Pallas Capital Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Pallas Capital Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,316	Closed	-$200K	–	525
2024 Q1	$200K	Sell	8,316 -12,203	-59%	-$286K	0.01%	420
2023 Q4	$472K	Sell	20,519 -9,729	-32%	-$195K	0.03%	275
2023 Q3	$536K	Buy	30,248 +12,407	+70%	+$278K	0.03%	224
2023 Q2	$428K	Buy	+17,841	New	+$428K	0.02%	203

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Pallas Capital Advisors's IDNA Position: Q2 2024 in Review

Pallas Capital Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2024, closing a stake of 8,316 shares — an estimated $200K sold.

Pallas Capital Advisors first reported a position in IDNA in Q2 2023 and held it in 4 quarters. The position peaked at $536K in Q3 2023. 62 funds tracked by Wall St. Rank hold IDNA as of Q2 2024.

Pallas Capital Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2024 after selling out during the quarter.
Pallas Capital Advisors sold 8,316 iShares Genomics Immunology and Healthcare ETF shares in Q2 2024, an estimated $200K.
Pallas Capital Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2023 and held it in 4 quarters.
Pallas Capital Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $536K in Q3 2023.
62 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2024.

Based on Pallas Capital Advisors's 13F filing for Q2 2024, filed 22 Jul 2024.